

DAFTAR PUSTAKA

- Akter, S., Goto, A. and Mizoue, T., 2017. Smoking and the risk of type 2 diabetes in Japan: A systematic review and meta-analysis. *Journal of epidemiology*, 27(12), pp.553–561. <https://doi.org/10.1016/j.je.2016.12.017>.
- Alshekhlee, A., Miles, J.D., Katirji, B., Preston, D.C. and Kaminski, H.J., 2009. Incidence and mortality rates of Myasthenia Gravis and myasthenic crisis in US hospitals. *Neurology*, 72(18), pp.1548–1554. <https://doi.org/10.1212/WNL.0b013e3181a41211>.
- Anderson, L.W. and Krathwol, D.R., 2001. *A Taxonomy for Learning, Teaching and Assessing: A Revision of Bloom's Taxonomy of Educational Objectives*.
- Ramani, A. (2014) "HUBUNGAN INDEKS PEMBANGUNAN MANUSIA DENGAN INDIKATOR PENYAKIT, LINGKUNGAN, DAN GIZI MASYARAKAT," *Jurnal Ikesma*, 10.
- Anlar, B., Şenbil, N., Köse, G. and Değerliyurt, A., 2005. Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years. *Neuromuscular Disorders*, 15(5), pp.355–357. <https://doi.org/10.1016/j.nmd.2005.01.010>.
- Anon. n.d. *Harrison's Principles of Internal Medicine. 2 vols (2015)*.
- Anon. n.d. Profil Kesehatan 2023_shol_23 mei 20231_PUBLISH.
- Ar-Rasily, O.K. and Dewi, P.K., 2016. Faktor-Faktor yang Mempengaruhi Tingkat Pengetahuan Orang Tua Mengenai Kelainan Genetik Penyebab Disabilitas Intelektual di Kota Semarang. *Jurnal Kedokteran Diponegoro*, 5(4).
- Badan Pusat Statistik Provinsi Di Yogyakarta. (2023). Indeks Pembangunan Manusia Daerah Istimewa Yogyakarta [Online]. Tersedia di: <https://yogyakarta.bps.go.id/id/pressrelease/2023/12/01/1345/indeks-pembangunan-manusia-daerah-istimewa-yogyakarta.html> (Diakses pada 6 Oktober 2024).
- Barraud, C., Desguerre, I., Barnerias, C., Gitiaux, C., Boulay, C. and Chabrol, B., 2018. Clinical features and evolution of juvenile Myasthenia Gravis in a French cohort. *Muscle & Nerve*, 57(4), pp.603–609. <https://doi.org/10.1002/mus.25965>.
- Beloor Suresh, A. and Asuncion, R.M.D., 2023. Myasthenia Gravis.
- Borsi, A., Nissinen, R., Gary, C., Noel, W., Lee, J., McCallion, J., Zhang, Q., Batista, A., Vavrinec, M., DeCourcy, J., Chatterton, E., Thomas, O. and Gibson, G., 2022. RWD104 Delayed Diagnosis Amongst gMG Patients: Results From a European Real-World Study. *Value in Health*, 25(12), pp.S468–S469. <https://doi.org/10.1016/j.jval.2022.09.2329>.
- Bujang, M.A. et al. (2024) "Sample size determination for conducting a pilot study to assess reliability of a questionnaire," *Restorative Dentistry & Endodontics*, 49(1). Available at: <https://doi.org/10.5395/rde.2024.49.e3>.
- Carr, A.S., Cardwell, C.R., McCarron, P.O. and McConville, J., 2010. A systematic review of population based epidemiological studies in Myasthenia Gravis. *BMC Neurology*, 10(1), p.46. <https://doi.org/10.1186/1471-2377-10-46>.

- Ciafaloni, E., 2019. Myasthenia Gravis and Congenital Myasthenic Syndromes. *CONTINUUM: Lifelong Learning in Neurology*, 25(6), pp.1767–1784. <https://doi.org/10.1212/CON.0000000000000800>.
- DeCoster, J., Gallucci, M., & Iselin, A.-M. R. (2011). Best Practices for Using Median Splits, Artificial Categorization, and their Continuous Alternatives. *Journal of Experimental Psychopathology*, 2(2), 197–209. <https://doi.org/10.5127/jep.008310>
- Dishnica, N., Vuong, A., Xiong, L., Tan, S., Kovoor, J., Gupta, A., Stretton, B., Goh, R., Harroud, A., Schultz, D., Malycha, J. and Bacchi, S., 2023. Single count breath test for the evaluation of respiratory function in Myasthenia Gravis: A systematic review. *Journal of Clinical Neuroscience*, 112, pp.58–63. <https://doi.org/10.1016/j.jocn.2023.04.011>.
- Dragusin, A., Grecu, N., Ribigan, A.C., Badea, R.S., Terecoasa, E.O., Ene, A. and Tiu, C., 2022. Low Fluctuation of Symptoms May Delay Diagnosis of Myasthenia Gravis: A Case Series. *Neurology and Therapy*, 11(1), pp.481–487. <https://doi.org/10.1007/s40120-021-00312-w>.
- Dresser, L., Wlodarski, R., Rezanian, K. and Soliven, B., 2021. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. *Journal of Clinical Medicine*, 10(11), p.2235. <https://doi.org/10.3390/jcm10112235>.
- Engstrom, J., 2004. Myasthenia Gravis: Diagnostic Mimics. *Seminars in Neurology*, 24(02), pp.141–147. <https://doi.org/10.1055/s-2004-830903>.
- Erdian, 2009. *Ilmu Perilaku*. I ed. Jakarta: CV Sagung Seto.
- Fadare, J., Olamoyegun, M. and Gbadegesin, B., 2015. Medication Adherence and Direct Treatment Cost among Diabetes Patients Attending a Tertiary Healthcare Facility in Ogbomosho, Nigeria. *Malawi Medical Journal*, 27(2), p.65. <https://doi.org/10.4314/mmj.v27i2.7>.
- Fajri, N. and Syahrul, 2021. P-PN014. Demographic and clinical characteristics among patients with Myasthenia Gravis. *Clinical Neurophysiology*, 132(8), p.e110. <https://doi.org/10.1016/j.clinph.2021.02.265>.
- Fauziyah, N., Hariyati, R.T.S., Rachmi, S.F., Handiyani, H. and Simarmata, R., 2021. Hubungan Fungsi Manajemen Kepala Ruang dengan Pelibatan Pasien (Patient Engagement) dalam Asuhan Keperawatan di Masa Pandemi Covid-19. *Jurnal Kepemimpinan dan Manajemen Keperawatan*, 4(2), pp.121–134. <https://doi.org/10.32584/jkkm.v4i2.1230>.
- Foright, R.M., Presby, D.M., Sherk, V.D., Kahn, D., Checkley, L.A., Giles, E.D., Bergouignan, A., Higgins, J.A., Jackman, M.R., Hill, J.O. and MacLean, P.S., 2018. Is regular exercise an effective strategy for weight loss maintenance? *Physiology & behavior*, 188, pp.86–93. <https://doi.org/10.1016/j.physbeh.2018.01.025>.
- Gajdos, P., Chevret, S., Clair, B., Tranchant, C. and Chastang, C., 1997. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in Myasthenia Gravis. *Annals of Neurology*, 41(6), pp.789–796. <https://doi.org/10.1002/ana.410410615>.
- Gelfand, E.W., 2012. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. *New England Journal of Medicine*, 367(21), pp.2015–2025. <https://doi.org/10.1056/NEJMra1009433>.

- Gronseth, G.S. and Barohn, R.J., 2000. Practice parameter: Thymectomy for autoimmune Myasthenia Gravis (an evidence-based review) [RETIRED]. *Neurology*, 55(1), pp.7–15. <https://doi.org/10.1212/WNL.55.1.7>.
- Hart, I.K., Sathasivam, S. and Sharshar, T., 2007. Immunosuppressive agents for Myasthenia Gravis. *Cochrane Database of Systematic Reviews*. <https://doi.org/10.1002/14651858.CD005224.pub2>.
- Hendricks, T.M., Bhatti, M.T., Hodge, D.O. and Chen, J.J., 2019. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study. *American Journal of Ophthalmology*, 205, pp.99–105. <https://doi.org/10.1016/j.ajo.2019.04.017>.
- Hendryadi, H. (2017) “VALIDITAS ISI: TAHAP AWAL PENGEMBANGAN KUESIONER,” *Jurnal Riset Manajemen dan Bisnis (JRMB) Fakultas Ekonomi UNIAT*, 2(2), pp. 169–178. Available at: <https://doi.org/10.36226/jrmb.v2i2.47>.
- Herrod, P.J.J., Doleman, B., Blackwell, J.E.M., O’Boyle, F., Williams, J.P., Lund, J.N. and Phillips, B.E., 2018. Exercise and other nonpharmacological strategies to reduce blood pressure in older adults: a systematic review and meta-analysis. *Journal of the American Society of Hypertension*, 12(4), pp.248–267. <https://doi.org/10.1016/j.jash.2018.01.008>.
- Howard, J.F., 2015. *Clinical Overview of Myasthenia Gravis*. Myasthenia Gravis Foundation of America.
- Hunter, G.R., Plaisance, E.P., Carter, S.J. and Fisher, G., 2018. Why intensity is not a bad word: Optimizing health status at any age. *Clinical nutrition (Edinburgh, Scotland)*, 37(1), pp.56–60. <https://doi.org/10.1016/j.clnu.2017.02.004>.
- I Ketut Swarjana, 2012. *Metodologi Penelitian Kesehatan*. 1st ed. Yogyakarta: ANDI.
- Ichikawa, J.J. and Steup, M., 2018. *The Analysis of Knowledge*. The Stanford Encyclopedia of Philosophy.
- Jaretzki, A., Penn, A.S., Younger, D.S., Wolff, M., Olarte, M.R., Lovelace, R.E. and Rowland, L.P., 1988. ‘Maximal’ thymectomy for Myasthenia Gravis. Results. *The Journal of thoracic and cardiovascular surgery*, 95(5), pp.747–57.
- Jayam Truth, A., Dabi, A., Solieman, N., Kurukumbi, M. and Kalyanam, J., 2012. Myasthenia Gravis: A Review. *Autoimmune Diseases*, 2012, pp.1–10. <https://doi.org/10.1155/2012/874680>.
- Juel, V.C. and Massey, J.M., 2007. Myasthenia Gravis. *Orphanet Journal of Rare Diseases*, 2(1), p.44. <https://doi.org/10.1186/1750-1172-2-44>.
- Keane, J., 1986. Vertical Diplopia. *Seminars in Neurology*, 6(02), pp.147–154. <https://doi.org/10.1055/s-2008-1041458>.
- Kjeldsen, S.E., 2018. Hypertension and cardiovascular risk: General aspects. *Pharmacological Research*, 129, pp.95–99. <https://doi.org/10.1016/j.phrs.2017.11.003>.
- Kupersmith, M.J., 2009. Ocular Myasthenia Gravis: treatment successes and failures in patients with long-term follow-up. *Journal of Neurology*, 256(8), pp.1314–1320. <https://doi.org/10.1007/s00415-009-5120-8>.

- KUTLUK, G., YAYICI KÖKEN, Ö., MIHÇI, F. and ÖZ TUNÇER, G., 2022. Duchenne Musküler Distrofide Pediatri Uzmanları ve Pediatri Uzmanlık Öğrencilerinin Bilgi, Tutum ve Uygulamalarının Değerlendirilmesi. *Turkish Journal of Pediatric Disease*, pp.1–7. <https://doi.org/10.12956/tchd.974974>.
- Lancaster, L. and Stillman, D.L. (2003) “When generations collide: who they are, why they clash, how to solve the generational puzzle at work,” *Choice Reviews Online*, 40(11), pp. 40-6507-40–6507. <https://doi.org/10.5860/CHOICE.40-6507>.
- Lakhan, R., & Sharma, M. (2010). Knowledge, attitudes, and practices (KAP) survey of families toward their children with intellectual disability in Barwani, India. *Asia Pacific Disability Rehabilitation Journal*, 21, 101–117.
- Mahic, M., Bozorg, A., DeCourcy, J., Golden, K., Gibson, G., Taylor, C. and Scowcroft, A., 2023. Physician- and patient-reported perspectives on Myasthenia Gravis in Europe: a real-world survey. *Orphanet Journal of Rare Diseases*, 18(1), p.169. <https://doi.org/10.1186/s13023-023-02727-0>.
- Mahic, M., Bozorg, A.M., DeCourcy, J.J., Golden, K.J., Gibson, G.A., Taylor, C.F., Ting, A., Story, T.J. and Scowcroft, A., 2022. Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey. *Neurology and Therapy*, 11(4), pp.1535–1551. <https://doi.org/10.1007/s40120-022-00383-3>.
- Melzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., Melms, A., Tackenberg, B., Schalke, B., Schneider-Gold, C., Zimprich, F., Meuth, S.G. and Wiendl, H., 2016. Clinical features, pathogenesis, and treatment of Myasthenia Gravis: a supplement to the Guidelines of the German Neurological Society. *Journal of Neurology*, 263(8), pp.1473–1494. <https://doi.org/10.1007/s00415-016-8045-z>.
- Nair, A., Patil-Chhablani, P., Venkatramani, D. and Gandhi, R., 2014. Ocular Myasthenia Gravis: A review. *Indian Journal of Ophthalmology*, 62(10), p.985. <https://doi.org/10.4103/0301-4738.145987>.
- NINDS, 2023. Myasthenia Gravis. NIH.
- Nur, M. (2021). ANALISIS KELEMAHAN PENGATURAN PENGUPAHAN BAGI PROFESI DOKTER DI INDONESIA. *Jilid*, 50(3), 2527–4716.
- Oosterhuis, H.J., 1989. The natural course of Myasthenia Gravis: a long term follow up study. *Journal of Neurology, Neurosurgery & Psychiatry*, 52(10), pp.1121–1127. <https://doi.org/10.1136/jnnp.52.10.1121>.
- Owe, J.F., 2006. Causes of death among patients with Myasthenia Gravis in Norway between 1951 and 2001. *Journal of Neurology, Neurosurgery & Psychiatry*, 77(2), pp.203–207. <https://doi.org/10.1136/jnnp.2005.072355>.
- Palace, J., Newsom-Davis, J. and Lecky, B., 1998. A randomized double-blind trial of prednisolone alone or with azathioprine in Myasthenia Gravis. *Neurology*, 50(6), pp.1778–1783. <https://doi.org/10.1212/WNL.50.6.1778>.
- Pasqualin, F., Guidoni, S. V., Ermani, M., Pegoraro, E. and Bonifati, D.M., 2020. Outcome measures and treatment effectiveness in late onset Myasthenia Gravis. *Neurological Research and Practice*, 2(1), p.45. <https://doi.org/10.1186/s42466-020-00091-z>.

- Roper, J., Fleming, M.E., Long, B. and Koyfman, A., 2017. Myasthenia Gravis and Crisis: Evaluation and Management in the Emergency Department. *The Journal of Emergency Medicine*, 53(6), pp.843–853. <https://doi.org/10.1016/j.jemermed.2017.06.009>.
- Schröder, A., Linker, R.A. and Gold, R., 2009. Plasmapheresis for neurological disorders. *Expert Review of Neurotherapeutics*, 9(9), pp.1331–1339. <https://doi.org/10.1586/ern.09.81>.
- Sesrianty, V., 2008. Hubungan Pendidikan dan Masa Kerja dengan Keterampilan Perawat Melakukan Tindakan Bantuan Hidup Dasar. *Jurnal Kesehatan Perintis*, 5(2).
- Shah, K.A., 2023. Myasthenia Gravis *Clinical Presentation*. Medscape.
- Siagian, E., 2020. Hubungan Pengetahuan dan Sikap Tenaga Kesehatan terhadap Kematian Tentang Keperawatan Paliatif. *CHMK Nursing Scientific Journal*, 4(3).
- Sieb, J.P., 2014. Myasthenia Gravis: an update for the clinician. *Clinical and Experimental Immunology*, 175(3), pp.408–418. <https://doi.org/10.1111/cei.12217>.
- Sih, M., Soliven, B., Mathenia, N., Jacobsen, J. and Rezanja, K., 2017. Head-drop: A frequent feature of late-onset Myasthenia Gravis. *Muscle & Nerve*, 56(3), pp.441–444. <https://doi.org/10.1002/mus.25526>.
- Skeie, G.O., Apostolski, S., Evoli, A., Gilhus, N.E., Illa, I., Harms, L., Hilton-Jones, D., Melms, A., Verschuuren, J. and Horge, H.W., 2010. Guidelines for treatment of autoimmune neuromuscular transmission disorders. *European Journal of Neurology*, 17(7), pp.893–902. <https://doi.org/10.1111/j.1468-1331.2010.03019.x>.
- STANDAR KOMPETENSI DOKTER INDONESIA KONSIL KEDOKTERAN INDONESIA Indonesian Medical Council Jakarta 2012 KONSIL KEDOKTERAN INDONESIA (no date).
- Stickler, D.E., 2019. *Lambert-Eaton Myasthenic Syndrome (LEMS)*. Medscape.
- Suharsimi Arikunto, 2011. *Prosedur penelitian : suatu pendekatan praktik*. 14th ed. Jakarta: Rineka Cipta.
- Suzuki, S., Nishimoto, T., Kohno, M., Utsugisawa, K., Nagane, Y., Kuwana, M. and Suzuki, N., 2013. Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated Myasthenia Gravis. *Journal of Neuroimmunology*, 258(1–2), pp.61–66. <https://doi.org/10.1016/j.jneuroim.2013.03.001>.
- Synmon, B., Rawat, S., Kynta, R., Hussain, M., Sharma, S., Lyngdoh, B., Wankhar, B. and Hynniewta, Y., 2022. Clinical spectrum of Myasthenia Gravis: An institute experience over 8 years from North East India. *Journal of Family Medicine and Primary Care*, 11(11), p.7158. <https://doi.org/10.4103/jfmpe.jfmpe.617.22>.
- Wang, L., Zhang, Y. and He, M., 2017. Clinical predictors for the prognosis of Myasthenia Gravis. *BMC Neurology*, 17(1), p.77. <https://doi.org/10.1186/s12883-017-0857-7>.

- Witte, A.S., Cornblath, D.R., Parry, G.J., Lisak, R.P. and Schatz, N.J., 1984. Azathioprine in the treatment of Myasthenia Gravis. *Annals of Neurology*, 15(6), pp.602–605. <https://doi.org/10.1002/ana.410150615>.
- Wulandari, A.S. and Ahmad, N.F.S., 2020. Hubungan Faktor Sosiodemografi terhadap Tingkat Pengetahuan Swamedikasi di Beberapa Apotek Wilayah Purworejo. *Indonesian Pharmacy and Natural Medicine Journal*, 4(1).
- Zamanzadeh, V. *et al.* (2015) “Design and Implementation Content Validity Study: Development of an instrument for measuring Patient-Centered Communication,” *Journal of Caring Sciences*, 4(2), pp. 165–178. Available at: <https://doi.org/10.15171/jcs.2015.017>.
- Zhang, J., Chen, Y., Chen, J., Huang, X., Wang, H., Li, Y., Liu, W. and Feng, H., 2021. AChRAb and MuSKAb double-seropositive Myasthenia Gravis: a distinct subtype? *Neurological Sciences*, 42(3), pp.863–869. <https://doi.org/10.1007/s10072-021-05042-3>.